Clinical Trials for Women’s Cancers

Home › Patient Care  › Gynecologic Oncology › Clinical Trials for Women’s Cancers

Medical College of Wisconsin physicians who specialize in gynecologic cancers collaborate with researchers and academic medical centers around the country to advance the understanding and treatment of ovarian, cervical, uterine, vulvar and vaginal cancers. Their patients – and the entire region – are the direct beneficiaries of ongoing research.

The Gynecologic Cancer Program is an active member of the Gynecologic Oncology Group (GOG), an organization that coordinates multi-center clinical trials to advance the treatment of gynecologic cancers. The program is also involved with the Radiation Therapy Oncology Group (RTOG). Both are cooperative research groups funded by the National Cancer Institute.

Our physicians are also working to establish a Women’s Health Research Initiative and a tissue bank to advance the understanding of female cancers.

Ongoing studies provide access to the best research has to offer in advanced treatments and improved quality of life.

The following clinical trials are open to enrollment.

To obtain information regarding any gynecologic clinical trials that our department has open, please contact our research team at 1-855-771-9477 or Email Us.

Type of CancerProtocol ID & Study Title
Any cancer being treated with carboplatinNRG-GY022
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin

Keywords: dMMR, DNA mismatch repair, Mismatch Repair Deficient, Early Stage, High Intermediate Rick, newly diagnosed, Pembrolizumab, Immunotherapy
EndometrialNRG-GY026
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma

Keywords: Endometrial cancer, HER-2 positive
EndometrialSutro- STRO-002-GM1
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha (FolRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

Keywords: Advance Epithelial Ovarian Cancer, Fallopian Tube, Primary Peritoneal and Endometrial Cancer, Folate Receptor Alpha
EndometrialNRG-GY028
This study is being done to answer if we can lower the chance of endometrial cancer growing or spreading by adding the drug ipatasertib to treatment with a hormonal drug. The study is divided into two portions, a Phase I portion and a Phase II portion. In the phase I portion of this trial, we want to test the safety of a drug called ipatasertib, by testing different doses of the drug to see which dose is safer for people when given in combination with a fixed dose of a drug called megestrol acetate (MA). The dose of the usual treatment drug stays the same while the dose of the additional drug can be adjusted to determine the best dose. In the Phase II portion of the study we can test how safe the treatment is and how well it works.

Keywords: Endometrial Cancer, Recurrent
OvarianNRG-CC008
A Study to Compare Two Surgical Procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) in Women With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Keywords: BRCA1 Mutations, Salpingectomy, Oophorectomy
Ovary, EndometrialGOG-3082-ACRIVON-ACR-368-201
In this study, ACR-368 is being tested when it is given alone (called monotherapy) and when it is combined with low doses of a chemotherapy medication named gemcitabine (called combination study therapy). The main purpose of this study is to investigate how effective ACR-368 is in treating ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma in a population selected based on subjects who test OncoSignature Positive.

Keywords: Ovarian Cancer, Endometrial Cancer, Platinum Resistant , OncoSignature
Ovarian, primary peritoneal, or fallopian tube cancerNRG-GY027
A Phase 1 study to test adding ipatasertib with the initial standard of chemotherapy, will have a better result in treating the patients with newly diagnosed ovarian cancer. The safety, side effects, and best dose of ipatasertib will also be determined in this study

Keywords: Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Female Genital Neoplasms
Ovarian, primary peritoneal, or fallopian tube cancerGOG-3049-MER-XMT1536-3-UP-NEXT
Phase 3, multi-center randomized study of XMT-1536 (upifitamab rilsodotin) in patients with tumors expressing high levels of NaPi2b, focusing on patients with recurrent, platinum-sensitive high-grade serous ovarian cancer (HGSOC) including fallopian tube and primary peritoneal cancer. This study will assess the progression free survival (the length of time that participants live without their disease getting worse) for participants with ovarian cancer with high NaPi2b.

Keywords: Ovarian cancer, platinum sensitive, recurrent cancer, randomized
Ovarian, primary peritoneal, or fallopian tube cancerGOG-3081-PRESERVE-004-MK3475

The study compares two doses of ONC-392 in combination with a fixed dose of pembrolizumab in participants with ovarian cancer who are resistant to platinum-based chemotherapy and have disease progression on line of therapy containing bevacizumab. Results from this study will be used to inform the study design, patient population, and dose selection for future studies in advanced ovarian cancer.

Keywords: Ovarian Cancer, Platinum Resistant, ONC-392
Ovarian, primary peritoneal, or fallopian tube cancerGOG-3073-CORT125134-556 / ROSELLA

This phase 3 study to test the effect of Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer. As there are no currently approved therapies or effective standard of care for heavily pretreated patients with ovarian cancer who have exhausted single-agent chemotherapy and/or bevacizumab, the combination of intermittently administered relacorilant and nab-paclitaxel may demonstrate a substantial improvement without increased toxicity compared with nab-paclitaxel. Patients will receive study treatment until confirmed progressive disease (PD) or unacceptable toxicity. All patients will be followed for the collection of study endpoints, inclusive of disease progression and survival

Keywords: Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Female Genital Neoplasms
Ovarian, primary peritoneal, or fallopian tube cancerSTRO-002-GM2
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer Ovarian, primary peritoneal, or Fallopian Tube Cancer

Keywords: STRO-002, Phase 1, Bevacizumab, Refractory, Platinum Resistant, Dose Expansion, Anti-Folate Receptor Alpha Antibody Drug Conjugate, Advanced Epithelial Ovarian Cancer, Measurable Disease, High Grade Serous
Kidney transplantOBG-IIT-UYAR-HPV-MISP-61451

In this study, we want to learn how people with suppressed immune systems (e.g.-those undergoing an organ transplant) respond to HPV vaccine. We plan to study people who receive the vaccine before they undergo a kidney transplant and those who receive the vaccine after they undergo a kidney transplant to document the difference in the immune response to the vaccine compared to people who are not immune suppressed.


Keywords: Kidney Transplant, Immune Response, Vaccine, HPV